{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thromboembolic+Events&page=2",
    "query": {
      "condition": "Thromboembolic Events",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thromboembolic+Events&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:55:33.647Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04041843",
      "title": "Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2017-06-02",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041843"
    },
    {
      "nct_id": "NCT03068923",
      "title": "Thrombosis Outcomes in Pediatric Venous Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 120,
      "start_date": "2016-05",
      "completion_date": "2022-03-09",
      "has_results": false,
      "last_update_posted_date": "2025-01-31",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03068923"
    },
    {
      "nct_id": "NCT03075761",
      "title": "Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post Thrombotic Syndrome",
        "Deep Vein Thrombosis"
      ],
      "interventions": [
        {
          "name": "Fitbit",
          "type": "DEVICE"
        },
        {
          "name": "30-minute education session",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "7 Years to 21 Years"
      },
      "enrollment_count": 111,
      "start_date": "2016-11-18",
      "completion_date": "2019-10-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-18",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03075761"
    },
    {
      "nct_id": "NCT03292666",
      "title": "Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism",
        "Anticoagulants and Bleeding Disorders"
      ],
      "interventions": [
        {
          "name": "Oral Anticoagulant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39603,
      "start_date": "2010-01-01",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Pasadena, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03292666"
    },
    {
      "nct_id": "NCT03465735",
      "title": "Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute DVT of Lower Extremity"
      ],
      "interventions": [
        {
          "name": "Vascular Boot",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-01-13",
      "completion_date": "2020-01-03",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465735"
    },
    {
      "nct_id": "NCT02342444",
      "title": "Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trauma",
        "Surgery",
        "Deep Vein Thrombosis (DVT)",
        "Thromboembolic Events"
      ],
      "interventions": [
        {
          "name": "Enoxaparin Sodium Injection 30 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin Sodium Injection 40 mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "15 Years to 100 Years"
      },
      "enrollment_count": 606,
      "start_date": "2014-02",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342444"
    },
    {
      "nct_id": "NCT01608919",
      "title": "Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "blood tests",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2012-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-08-10",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01608919"
    },
    {
      "nct_id": "NCT05111613",
      "title": "The PEERLESS Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Pulmonary Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Catheter-Directed Thrombolysis",
          "type": "DEVICE"
        },
        {
          "name": "FlowTriever System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Inari Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 692,
      "start_date": "2022-02-14",
      "completion_date": "2024-04-11",
      "has_results": true,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 56,
      "location_summary": "Loma Linda, California • Orange, California • Pasadena, California + 46 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05111613"
    },
    {
      "nct_id": "NCT02829957",
      "title": "RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Menstruation"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2016-09",
      "completion_date": "2020-02-13",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829957"
    },
    {
      "nct_id": "NCT02585713",
      "title": "Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Vein Thrombosis",
        "Deep Vein Thrombosis",
        "Gonadal Thrombosis",
        "Hepatic Thrombosis",
        "Malignant Neoplasm",
        "Mesenteric Thrombosis",
        "Metastatic Malignant Neoplasm",
        "Portal Vein Thrombosis",
        "Pulmonary Embolism",
        "Renal Vein Thrombosis",
        "Splenic Thrombosis",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2015-11-20",
      "completion_date": "2019-12-24",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-06-11T02:55:33.647Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585713"
    }
  ]
}